MedTrace Logo

4D-310 in Adults With Fabry Disease and Cardiac Involvement

NCT05629559 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-02-21

No results posted yet for this study

Summary

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

Conditions

Interventions

BIOLOGICAL

4D-310

Single IV administration of 4D-310

Sponsors & Collaborators

  • 4D Molecular Therapeutics

    lead INDUSTRY

Principal Investigators

  • Alan H Cohen, MD · 4D Molecular Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-16
Primary Completion
2026-06-30
Completion
2030-06-30
FDA Drug
Yes

Countries

  • Australia
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05629559 on ClinicalTrials.gov